Also categorized in Business of Medicine:
Targeting the Type I Interferon Pathway to Treat Patients With Lupus
x hide permanently

NUS Researchers Discover Possible New Treatment Option for Aggressive Forms of Breast Cancer

EurekAlert! Science News Releases

Photo: Pixabay

EurekAlert.org

Women diagnosed with the biologically aggressive triple-negative (TNBC) and endocrine-refractory subtypes of breast cancer confront a bleak prognosis because they respond poorly to conventional chemotherapy. Researchers from the NUS Yong Loo Lin School of Medicine have discovered that combining one of the most widely prescribed medication class for type 2 diabetes mellitus known as thiazolidinediones (TZD), with an emerging class of cancer drugs known as histone deacetylase inhibitors, elicits robust anti-tumor responses in preclinical models of these breast cancer subtypes.

In the study led by Assistant Professor Alan Prem Kumar from the NUS Centre for Cancer ...